Herantis Pharma Oyj, a clinical stage biotechnology company, engages in the development of disease-modifying cerebral dopamine neurotrophic factor (CDNF) based therapies for Parkinson's disease (PD). The company's lead product in pipeline includes HER-096, an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein that is in phase 1b clinical trial for the treatment of PD and other neurodegenerative diseases. Herantis Pharma Oyj was incorporated in 2008 and is based in Espoo, Finland.
Frequently asked questions
What sector does Herantis Pharma Oyj (HRTIS) operate in?
Herantis Pharma Oyj belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Herantis Pharma Oyj (HRTIS) current stock price?
As of the latest data, Herantis Pharma Oyj stock price is €1.76, with a previous close of €1.65. Herantis Pharma Oyj gained €0.11 in the last trading session, representing a 6.54% increase.
What is Herantis Pharma Oyj (HRTIS) current market capitalization?
Herantis Pharma Oyj market cap is approximately 46.65 million.
What is Herantis Pharma Oyj (HRTIS) Earnings Per Share (EPS)?
The trailing EPS is -€0.28, and the forward EPS is -€0.18.
Does Herantis Pharma Oyj (HRTIS) pay dividends?
No. Herantis Pharma Oyj does not pay a dividend.
What is Herantis Pharma Oyj (HRTIS) beta (volatility) score?
Herantis Pharma Oyj has a beta of 0.600, indicating lower volatility than the overall market.